Rep. Josh Gottheimer Buys Natera, Inc. (NASDAQ:NTRA) Stock

Key Points

• Representative Josh Gottheimer purchased shares of Natera, Inc. (NASDAQ:NTRA) valued between $1,001 and $15,000 on September 22nd, as disclosed in a recent filing.
• Natera reported a quarterly revenue of $546.60 million, exceeding analyst expectations of $476.84 million, despite missing the earnings per share consensus estimate.
• Wall Street analysts maintain a positive outlook for Natera, with an average rating of "Moderate Buy" and a consensus price target of $196.81 for the stock.

Representative Josh Gottheimer (D-New Jersey) recently bought shares of Natera, Inc. NASDAQ: NTRA. In a filing disclosed on October 15th, the Representative disclosed that they had bought between $1,001 and $15,000 in Natera stock on September 22nd. The trade occurred in the Representative's "MORGAN STANLEY - SELECT UMA ACCOUNT # 1" account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Baldwin Insurance Group NASDAQ: BWIN on 9/23/2025.
• Purchased $1,001 - $15,000 in shares of CommVault Systems NASDAQ: CVLT on 9/23/2025.
• Purchased $1,001 - $15,000 in shares of Sysmex OTCMKTS: SSMXY on 9/22/2025.
• Purchased $1,001 - $15,000 in shares of Independence Realty Trust NYSE: IRT on 9/22/2025.
• Sold $1,001 - $15,000 in shares of Diageo NYSE: DEO on 9/22/2025.
• Purchased $1,001 - $15,000 in shares of Tandem Diabetes Care NASDAQ: TNDM on 9/22/2025.
• Sold $1,001 - $15,000 in shares of Trade Desk NASDAQ: TTD on 9/11/2025.
• Sold $1,001 - $15,000 in shares of Intuitive Surgical NASDAQ: ISRG on 9/3/2025.
• Purchased $1,001 - $15,000 in shares of Natera NASDAQ: NTRA on 8/22/2025.
• Sold $1,001 - $15,000 in shares of Sysmex OTCMKTS: SSMXY on 8/21/2025.

Natera Stock Up 0.6%

Shares of Natera stock opened at $180.54 on Friday. The firm's 50 day moving average price is $167.60 and its 200-day moving average price is $158.07. Natera, Inc. has a 52-week low of $117.27 and a 52-week high of $187.34. The company has a market cap of $24.78 billion, a P/E ratio of -94.52 and a beta of 1.74.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm had revenue of $546.60 million during the quarter, compared to analysts' expectations of $476.84 million. During the same period in the prior year, the firm posted ($0.30) earnings per share. Natera's revenue for the quarter was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Transactions at Natera

In other news, CEO Steven Leonard Chapman sold 14,083 shares of the company's stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $160.00, for a total value of $2,253,280.00. Following the sale, the chief executive officer owned 154,072 shares in the company, valued at $24,651,520. This represents a 8.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Solomon Moshkevich sold 3,000 shares of the company's stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $159.99, for a total value of $479,970.00. Following the completion of the sale, the insider owned 117,559 shares in the company, valued at $18,808,264.41. The trade was a 2.49% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 72,464 shares of company stock valued at $10,963,125. 5.63% of the stock is owned by insiders.

Institutional Investors Weigh In On Natera

A number of large investors have recently bought and sold shares of NTRA. Bank of Jackson Hole Trust purchased a new stake in shares of Natera in the 1st quarter valued at $29,000. Rakuten Securities Inc. boosted its holdings in Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after purchasing an additional 119 shares during the last quarter. ORG Partners LLC purchased a new stake in Natera in the first quarter valued at $32,000. TCTC Holdings LLC boosted its holdings in Natera by 114.8% in the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock valued at $33,000 after purchasing an additional 124 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its holdings in Natera by 83.5% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company's stock valued at $33,000 after purchasing an additional 106 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on NTRA. Canaccord Genuity Group restated a "buy" rating and set a $200.00 target price on shares of Natera in a research note on Tuesday. Cowen restated a "buy" rating on shares of Natera in a research note on Friday, August 8th. Evercore ISI upgraded Natera to a "strong-buy" rating and set a $170.00 price target on the stock in a research note on Monday, July 28th. Piper Sandler reissued an "overweight" rating and set a $220.00 target price (up previously from $210.00) on shares of Natera in a research report on Monday, August 11th. Finally, Stephens reissued an "overweight" rating and set a $183.00 target price on shares of Natera in a research report on Friday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $196.81.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027. Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2026 election. Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025. Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.